Duncan Morpeth

Senior Director
Leads the Yorkshire and North East Corporate Finance team
10+ years of experience advising founder-owners, private equity and corporates
Provides M&A services, including business exits, fund raising/partial exits, and acquisition support
Leeds
@alvarezmarsal
LinkedIn
Copied!
Duncan Morpeth is a Senior Director with Alvarez & Marsal Corporate Finance in Leeds. He leads the Yorkshire and North East team. 

Mr. Morpeth brings more than ten years of experience advising founder-owners, private equity and corporates on a range of mergers and acquisition services, including business exits, fund raising/partial company exits, and acquisition support. 

Mr. Morpeth’s recent experience includes advising Primary Care Physio on its minority investment from BGF, the sale of Mosaic Fulfilment Solutions to Lloyds Development Capital, the sale of Palatine-backed Veincentre to Close Brothers Private Equity in a secondary buyout, the sale of Sandgate Systems (trading as “Every”) to Iris Software Group, the sale of DAM Structures to Severfield plc, and the acquisition of Plenitude Consulting by Growth Capital Partners.

Prior to joining A&M, Mr. Morpeth spent thirteen years with Grant Thornton, serving most recently as Director.

Mr. Morpeth earned a bachelor’s degree in English literature from the University of Leeds. A member of the Institute of Chartered Accountants in England and Wales (ICAEW), he recently won the ‘Rising Star of the Year’ award given by the Yorkshire Rainmaker Awards.

Insights By This Professional

According to the Institute of Public Policy Research, presenteeism, or working whilst sick, cost the UK economy £25bn in 2023, whilst absenteeism cost an additional £5bn. To address these challenges, many workplaces now emphasise proactive, value-added services for employee wellbeing and performance, delivered both on-site and online. This shift has spurred growth in the Occupational Health market, attracting significant interest from financial investors and strategic acquirers.
Latest insights The latest insights from Duncan Morpeth's team
Thought Leadership
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
Contact me
FOLLOW & CONNECT WITH A&M